Key Immunological Disorders

Why This Matters

Understanding immunological disorders is essential because they reveal what happens when the immune system's carefully balanced mechanisms go wrong. You're being tested on the fundamental concepts of self-tolerance, hypersensitivity reactions, autoantibody production, and immune deficiency, and these disorders are the clinical manifestations of those breakdowns. Whether the immune system attacks its own tissues, overreacts to harmless substances, or fails to function at all, each disorder category demonstrates a specific immunological principle.

Don't just memorize disease names and symptoms. Know what mechanism is failing in each disorder, which immune components are involved (T cells, B cells, antibodies, complement), and how the disorders relate to each other conceptually. Exam questions frequently ask you to compare disorders that share underlying mechanisms or to identify which immune pathway is disrupted based on clinical presentation.

---

Autoimmune Disorders: Loss of Self-Tolerance

These conditions occur when the immune system fails to distinguish self from non-self, producing autoantibodies or autoreactive T cells that attack the body's own tissues. The underlying problem is a breakdown of central tolerance (failure to delete self-reactive clones in the thymus or bone marrow) or peripheral tolerance (failure of mechanisms like regulatory T cells, anergy, or activation-induced cell death that normally keep escaped self-reactive cells in check).

Systemic Lupus Erythematosus (SLE)

• Multi-organ autoimmune attack: the immune system produces autoantibodies against nuclear components, most notably anti-dsDNA and anti-Smith (anti-Sm) antibodies. These bind to nuclear debris released from dying cells, forming antigen-antibody complexes that circulate through the blood.
• Type III hypersensitivity drives much of the pathology. Those circulating immune complexes deposit in small blood vessels of the kidneys (lupus nephritis), joints, skin, and serosal surfaces, activating complement and recruiting neutrophils that damage surrounding tissue.
• Female predominance (approximately 9:1 ratio) suggests hormonal influences on immune regulation, particularly estrogen's effects on B cell survival and activation thresholds. This makes SLE a classic example of sex-linked autoimmunity.
• Defective clearance of apoptotic debris is a key upstream mechanism. When dead cells aren't cleared efficiently, their nuclear contents become a persistent source of self-antigen, fueling the autoantibody response.

Rheumatoid Arthritis

• Symmetrical joint destruction: autoantibodies including rheumatoid factor (an IgM that binds the Fc region of IgG) and anti-CCP antibodies (targeting citrullinated proteins) are found in the synovial fluid and serum. These contribute to immune complex formation within joints.
• Pannus formation occurs when the inflamed synovial membrane proliferates aggressively, forming a mass of granulation tissue that invades and erodes cartilage and bone. This is a clear example of how chronic inflammation transitions from immune activation to structural tissue destruction.
• Systemic manifestations including cardiovascular disease, pulmonary nodules, and vasculitis show that autoimmune disorders rarely affect just one organ system, even when they have a primary target.

Type 1 Diabetes

• Organ-specific autoimmunity: autoreactive CD8+ cytotoxic T cells selectively destroy insulin-producing beta cells in the pancreatic islets of Langerhans. CD4+ T cells and macrophages also infiltrate the islets (a process called insulitis).
• Molecular mimicry may trigger disease when viral antigens (e.g., from Coxsackievirus B) structurally resemble beta cell proteins, activating cross-reactive T cells that then attack both the virus and the patient's own tissue.
• Autoantibodies against insulin, glutamic acid decarboxylase (GAD65), and islet cell antigens can be detected years before clinical onset, but the T cell response is the primary driver of beta cell destruction.
• Lifelong insulin dependence results because the immune system eliminates the body's capacity to produce insulin. Unlike Type 2 Diabetes (a metabolic disorder), the problem here is immune-mediated destruction, not insulin resistance.

Multiple Sclerosis

• Demyelination disorder: autoreactive CD4+ Th1 and Th17 cells attack myelin sheaths and oligodendrocytes in the central nervous system, disrupting saltatory conduction of nerve impulses. CD8+ T cells and macrophages also contribute to myelin destruction.
• Relapsing-remitting pattern in most patients reflects cycles of immune attack followed by partial remyelination and repair. Over time, repair capacity diminishes, and many patients transition to a progressive phase with accumulating disability.
• Blood-brain barrier (BBB) breakdown allows activated immune cells to cross into the CNS, which is normally an immune-privileged site with limited immune surveillance. Once inside, T cells are reactivated by local antigen-presenting cells displaying myelin antigens.

Inflammatory Bowel Disease (IBD)

• Mucosal immune dysregulation encompasses two major conditions: Crohn's disease (transmural inflammation that can affect any part of the GI tract, often with skip lesions) and ulcerative colitis (continuous mucosal inflammation limited to the colon and rectum).
• Th1/Th17 imbalance drives chronic inflammation, with excessive production of pro-inflammatory cytokines like TNF-α, IFN-γ, and IL-17 damaging intestinal epithelium. Regulatory T cell function is often impaired, failing to restrain this response.
• Environmental triggers interact with genetic susceptibility. Mutations in NOD2 (an intracellular pattern recognition receptor for bacterial peptidoglycan) are strongly associated with Crohn's disease, illustrating how defective innate immune sensing of gut microbiota can initiate chronic adaptive immune responses.

---

Autoantibody-Mediated Disorders: When Antibodies Cause Disease

In these conditions, autoantibodies directly cause pathology by binding to cell surface receptors or tissue components. The mechanism is Type II hypersensitivity, where antibodies either stimulate, block, or mark their targets for destruction (via complement activation or antibody-dependent cellular cytotoxicity).

Graves' Disease

• Stimulating autoantibodies: thyroid-stimulating immunoglobulin (TSI) binds the TSH receptor on thyroid follicular cells and activates it, mimicking TSH signaling. This drives excessive thyroid hormone production (hyperthyroidism) independent of normal pituitary feedback.
• Type II hypersensitivity (stimulatory subtype): unlike most autoantibodies that destroy their targets, TSI causes hyperfunction. The thyroid gland enlarges (diffuse goiter) because it's being constantly stimulated.
• Exophthalmos (bulging eyes) results from TSI cross-reacting with TSH receptors expressed on orbital fibroblasts, triggering inflammation and glycosaminoglycan deposition behind the eyes. This demonstrates how autoantibodies can affect multiple tissue sites that share the same receptor.

Myasthenia Gravis

• Blocking autoantibodies: antibodies target nicotinic acetylcholine receptors (AChRs) at the neuromuscular junction. They block acetylcholine binding, trigger receptor internalization, and activate complement-mediated destruction of the postsynaptic membrane.
• Fatigable weakness is the clinical hallmark. Muscle strength worsens with repeated use because fewer functional receptors remain available for neurotransmission. Rest partially restores function as remaining receptors become available again.
• Thymus abnormalities (thymoma in ~15% of patients, thymic hyperplasia in ~65%) suggest the thymus plays a role in generating or sustaining the autoreactive B cell clones that produce anti-AChR antibodies. Thymectomy can improve symptoms in many patients.

Psoriasis

• Keratinocyte hyperproliferation: T cell-derived cytokines, particularly IL-17 (from Th17 cells) and TNF-α, drive rapid skin cell turnover, creating the characteristic silvery scaly plaques on an erythematous base. Normal skin cell turnover takes about 28 days; in psoriasis, it's compressed to 3-5 days.
• Autoinflammatory component: psoriasis involves both adaptive immunity (autoreactive T cells) and innate immune activation (dendritic cells, neutrophils producing antimicrobial peptides like LL-37 that act as autoantigens). This blurs the line between autoimmune and autoinflammatory disease.
• Psoriatic arthritis develops in approximately 30% of patients, demonstrating how skin-directed autoimmunity can extend to joints and entheses (tendon insertion points).

---

Hypersensitivity Disorders: Inappropriate Immune Responses

These conditions result from exaggerated immune responses to external antigens that pose little or no actual threat. Type I hypersensitivity involves IgE-mediated mast cell degranulation, releasing histamine and other inflammatory mediators that cause rapid-onset symptoms.

Allergies and Asthma

• IgE-mediated Type I hypersensitivity: on first exposure to an allergen, Th2 cells drive B cells to produce allergen-specific IgE, which binds to FcεRI receptors on mast cells (sensitization). On re-exposure, the allergen cross-links surface-bound IgE, triggering mast cell degranulation and the release of histamine, leukotrienes, and prostaglandins.
• Th2 polarization is central to the allergic response. IL-4 promotes IgE class switching in B cells, IL-5 recruits and activates eosinophils, and IL-13 stimulates mucus production. This cytokine profile distinguishes allergic inflammation from other types of immune activation.
• Two-phase response: the early phase (minutes) is driven by preformed mediators like histamine causing vasodilation and bronchoconstriction. The late phase (6-12 hours later) involves recruited eosinophils and Th2 cells sustaining inflammation.
• Chronic airway remodeling in asthma demonstrates how repeated hypersensitivity reactions cause permanent structural changes, including smooth muscle hypertrophy, subepithelial fibrosis, and goblet cell hyperplasia.

---

Primary Immunodeficiency: When the Immune System Fails

These disorders result from intrinsic genetic defects in immune system development or function, leading to inadequate immune responses. Defects can affect B cells, T cells, phagocytes, or complement proteins, and each produces a characteristic pattern of susceptibility to specific pathogen types.

Primary Immunodeficiency Disorders

• Recurrent infections are the hallmark. The type of pathogen provides a diagnostic clue to which immune component is defective:
  • Antibody/B cell deficiency → recurrent infections with encapsulated bacteria (e.g., Streptococcus pneumoniae, Haemophilus influenzae) because opsonization is impaired
  • T cell deficiency → opportunistic infections with viruses, fungi (e.g., Candida, Pneumocystis), and intracellular bacteria, since cell-mediated immunity is compromised
  • Complement deficiency → susceptibility to Neisseria infections (especially terminal complement defects) and immune complex diseases resembling SLE (early complement defects)
  • Phagocyte defects → recurrent bacterial and fungal infections, often with abscess formation
• Key examples:
  • X-linked agammaglobulinemia (Bruton's): a mutation in BTK (Bruton's tyrosine kinase) blocks B cell maturation at the pre-B cell stage, resulting in near-absent circulating B cells and immunoglobulins. Patients present after ~6 months of age when maternal antibodies wane.
  • Severe Combined Immunodeficiency (SCID): defects in multiple genes (most commonly IL-2 receptor gamma chain, causing X-linked SCID) result in absent or nonfunctional T cells and B cells. Without treatment (bone marrow transplant or gene therapy), SCID is fatal in infancy.
• Secondary autoimmunity paradoxically develops in some immunodeficient patients. This seems counterintuitive, but it highlights that immune regulation requires functional regulatory T cells and proper immune cell homeostasis, not just immune cell quantity.

---

Quick Reference Table

---

Self-Check Questions

1. Graves' Disease and Myasthenia Gravis both involve autoantibodies targeting cell surface receptors. Explain how the same hypersensitivity type (Type II) produces opposite functional effects in these two disorders.

2. A patient presents with recurrent bacterial infections but handles viral infections normally. Which branch of the immune system is most likely defective: humoral (B cell/antibody) or cell-mediated (T cell)? Explain your reasoning based on how each branch targets different pathogen types.

3. Compare SLE and Type 1 Diabetes in terms of their target tissues, hypersensitivity mechanisms, and the primary immune effectors involved. Why is one considered systemic and the other organ-specific?

4. If asked to explain how the same fundamental defect (loss of self-tolerance) can produce different clinical outcomes, which three disorders would you choose as examples, and what makes each one mechanistically distinct?

5. What distinguishes Type I hypersensitivity disorders (like allergies) from autoimmune disorders at the level of antigen recognition and antibody class, even though both involve inappropriate immune activation?